Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-α and neutrophil elastase

被引:38
作者
Kohyama, T
Liu, XD
Zhu, YK
Wen, FQ
Wang, HJ
Fang, QH
Kobayashi, T
Rennard, SI
机构
[1] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA
[2] Univ Tokyo, Dept Resp Med, Tokyo, Japan
[3] Jincheng Hosp, Dept Resp Dis, Lanzhou, Peoples R China
[4] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
关键词
D O I
10.1165/rcmb.4818
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tissue destruction, resulting in emphysema, can be a consequence of several pathologic processes. The current study evaluated the effects of the phosphodiesterase (PDE)4 inhibitor, cilomilast, and other PDE inhibitors on the ability of fibroblasts to degrade extracellular matrix. Using the three-dimensional collagen gel culture system, fibroblasts (HFL-1) were cultured with tumor necrosis factor (TNF)-alpha, known to induce matrix metalloproteinase (MMP) release, and/or neutrophil elastase (NE), which can induce MMP activation. On Day 4, gels containing TNF-alpha and NE were significantly degraded (20.8 +/- 2.9% of original collagen content). Cilomilast (10 muM) inhibited this degradation (84.4 +/- 8.4%). Amrinone, a PDE3 inhibitor, and zaprinast, a PDES inhibitor, had no effect. Gelatin zymography and immunoblotting revealed that fibroblasts cultured with TNF-alpha released increased amounts of latent MMP-1 and -9. The addition of NE resulted in the conversion of MMP-1 and -9 to their active forms, indicative of collagen degradation. Cilomilast inhibited the release of MMP-1 and -9, as well as conversion of MMP-1 to its active form. Using real-time PCR analysis, cilomilast's effect on MMP-1 release was not associated with the proteinase's mRNA expression, suggesting that the inhibition of release is regulated at the post-transcriptional level. These results suggest that cilomilast may be a potentially effective therapeutic agent in diseases characterized by excessive tissue destruction, such as emphysema.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 37 条
[1]   Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro [J].
Alves, AC ;
Pires, ALA ;
Cruz, HN ;
Serra, MF ;
Diaz, BL ;
Cordeiro, RSB ;
Lagente, V ;
Martins, MA ;
Silva, PMRE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 312 (01) :89-96
[2]   The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation [J].
Banner, KH ;
Moriggi, E ;
DaRos, B ;
Schioppacassi, G ;
Semeraro, C ;
Page, CP .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (06) :1255-1261
[3]   PRODUCTION OF A TISSUE-LIKE STRUCTURE BY CONTRACTION OF COLLAGEN LATTICES BY HUMAN-FIBROBLASTS OF DIFFERENT PROLIFERATIVE POTENTIAL INVITRO [J].
BELL, E ;
IVARSSON, B ;
MERRILL, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (03) :1274-1278
[4]   SYNTHESIS AND ANALYTICAL USE OF A HIGHLY SENSITIVE AND CONVENIENT SUBSTRATE OF ELASTASE [J].
BIETH, J ;
SPIESS, B ;
WERMUTH, CG .
BIOCHEMICAL MEDICINE, 1974, 11 (04) :350-357
[5]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[6]   Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix matelloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line [J].
Brassart, B ;
Randoux, A ;
Hornebeck, W ;
Emonard, H .
CLINICAL & EXPERIMENTAL METASTASIS, 1998, 16 (06) :489-500
[7]   Expression of membrane type 1 matrix metalloproteinase in human articular cartilage [J].
Buttner, FH ;
Chubinskaya, S ;
Margerie, D ;
Huch, K ;
Flechtenmacher, J ;
Cole, AA ;
Kuettner, KE ;
Bartnik, E .
ARTHRITIS AND RHEUMATISM, 1997, 40 (04) :704-709
[8]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[9]  
Chubinskaya S, 1999, LAB INVEST, V79, P1669
[10]  
Deryugina EI, 1998, CANCER RES, V58, P3743